Close Menu

Myriad

There were more mergers and acquisitions in the omics space in 2018, reversing the decline experienced in 2017.

At the conference, researchers presented data from a number of studies using molecular diagnostic tools to better characterize breast cancer recurrence and treatment outcomes.

The studies involved data from 14,000 Hispanic women and showed the 87-SNP risk score outperformed its 86-SNP score for European women.

PacBio's shares skyrocketed 76 percent in November on the news that Illumina plans to acquire the firm for $1.2 billion in cash.

The company has entered into an accelerated share repurchase program with the bank to buy back a portion of its common stock.

Myriad CEO Mark Capone said earnings during the quarter exceeded expectations based on strong volume growth from hereditary cancer and new products.

During the meeting, researchers presented studies on combination immunotherapies and the efficacy of giving molecularly-informed treatments earlier in the disease continuum.

The test is approved to gauge germline BRCA mutations in advanced breast cancer patients who may benefit from treatment with Pfizer's PARP inhibitor Talzenna.

The analyst said Myraid's GeneSight and NIPT products present near-term opportunities that "should help power earnings upside in the years to come."

The new additions reflect data published this summer in the TAILORx trial, which speak to the chemopredictive ability of Genomic Health's Oncotype DX.

Pages

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

The Wall Street Journal examines billing codes used by uBiome.

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.